Analysis of Rates of Brain Metastases and Association With Breast Cancer Subtypes in Ontario, Canada
Open Access
- 12 August 2022
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (8) , e2225424
Abstract
Brain metastases (BRM) are a major cause of morbidity and mortality in women with breast cancer.1-5 Women with metastatic ERBB2 (formerly HER2)–positive and triple-negative breast cancer (TNBC) have a particularly high propensity to develop intracranial disease; in fact, over one-third of these women develop BRM during their lifetime.6-10 Although some systemic therapies have demonstrated intracranial activity, the mainstay of therapy for patients with breast cancer BRM remains local therapy, with radiation in the form of whole brain radiotherapy (WBRT) and/or stereotactic radiosurgery (SRS), as well as surgery in select cases.Keywords
This publication has 38 references indexed in Scilit:
- Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab eraThe Breast, 2013
- Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 studyThe Lancet Oncology, 2013
- Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: a prospective cohort studyBreast Cancer Research, 2012
- Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer NetworkCancer, 2012
- Incidence and time trends of brain metastases admissions among breast cancer patients in SwedenBritish Journal of Cancer, 2012
- Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast CancerClinical Cancer Research, 2010
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- A Modification of the Elixhauser Comorbidity Measures Into a Point System for Hospital Death Using Administrative DataMedical Care, 2009
- Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancerCancer, 2008
- Brain metastases in breast cancer: prognostic factors and managementBreast Cancer Research and Treatment, 2007